

## Annex 1. LAC epidemiologic studies

LAC assessed	Study name	Study type	N° of participants	Main results	Crude prevalence for LAC (%)	Representative publication	Other information
Cuba, Dominican Republic, Venezuela, Mexico, and Peru	The 10/66 Dementia Research Group	Epidemiologic comparison of developmental countries	14960	Compared with the 10/66 dementia algorithm, the DSM-IV dementia criterion might underestimate dementia prevalence, in regions with low awareness of this problematic.	5.0-7.7	Llibre R., et al. Lancet 2008; 372(9637): 464-74.	--
Chile	GERO cohort: Functional decline in Cognitive Complaint Cohort in community living elderly, Chile, 2017-2022	Follow-up study of community living elderly with cognitive complaint, through a population based study.	300 (to date 160 participants included)	Ongoing	--	None to date (protocol cohort in preparation)	Funding FONDAP Program Grant 15150012
Chile	Cost of dementia in Chile	Cross-sectional study.	330 patients with dementia and their caregivers	Average monthly cost per patient is estimated at US\$ 1463. Direct medical costs account for 20%, direct social costs for 5% and indirect costs for 75% of the total cost. The mean monthly cost is found to be inversely related to SES, a pattern largely driven by indirect costs.	--	Hojman DA., et al. Plos One 2017; 12(3): e0172204.	--
Chile	Burden of informal caregivers of people with Alzheimer's Disease and other dementias	Cross sectional survey	292 caregivers of dementia patients	80% were female; 63% presented severe burden, and 47% exhibited psychiatric morbidity.	--	--	--
Chile	Mortality of dementia and its geographical distribution	Observational Study of mortality registries	3852 dementia patients	3852 dementia deaths in 2012 (including 1585 Alzheimer's disease deaths). Dementia SMRs were increased in the Norte Grande (men: 126, 95% CI 100-159; women: 130, 95% CI 112-169) and the Zona Central,	--	Russ TC., et al. Dement Geriatr Cogn Disord. 2016; 42(1-2):31-41.	--
Chile	Health conditions and unmet needs for assistance to perform activities of daily living among older adults with dementia in Chile	Observational Study	4655 participants above 60 years old	People with dementia had worse health and needed greater assistance in performing daily activities than people without dementia. Being male was associated with more unmet needs,.	9.6	Zhou I., et al. Chile International Journal of Geriatric Psychiatry 2018; 33 (7): 964-971.	--

Brazil (Sao Paulo)	Sao Paulo Ageing & Health Study (SPAH)	Cross-sectional study	2072	Prevalence increased with age for both men and women after age 75, but was stable from 65 to 74 years. Low education and income were associated with increased risk of dementia.	5.1	Scazufca et al., International Psychogeriatrics 2008; 20:2,394–405	--
Brazil (Sao Paulo)	Sao Paulo Ageing & Health Study (SPAH)	Cross-sectional study	2005	Socioeconomic disadvantage in early life was associated with increased prevalence of dementia	5.1	Scazufca et al., International Journal of Epidemiology 2008;37:879–890	--
Brazil (Sao Paulo)	Sao Paulo Ageing & Health Study (SPAH)	Cross-sectional study	2003	Dementia was more prevalent amongst participants who were illiterate, had non-skilled occupations and lower income. Illiteracy, poor occupational achievement and low income accounted for 22.0%, 38.5% and 38.5% of the cases of dementia, respectively	--	Scazufca et al., International Psychogeriatrics 2010; 22:8,1209–1215	--
Brazil (Sao Paulo)	Sao Paulo Ageing & Health Study (SPAH)	Cross-sectional study	1373	After age adjustment, we found an association of subclinical hyperthyroidism and any type of dementia and vascular dementia. Analyzing data by gender, we found an association of subclinical hyperthyroidism with dementia and Alzheimer's disease only for men.	4.40	Benseñor et al. BMC Public Health 2010; 10:298	Grant research: FAPESP, SP, Brazil, Welcome Trust, London, UK and CNPq
Perú (Lima)	Dementia prevalence in a Lima, Peru urban community: door-to-door study	Cross-sectional study	1532	Alzheimer's disease was the most frequent diagnosis (56,2%). Dementia prevalence increased with age mainly in females. Age, female sex and low education correlated with dementia prevalence.	6.85	Custodio et al. An Fac Med 2008; 69 (4): 233-238	
Perú (Lima)	Cost-of-illness study in a retrospective cohort of patients with dementia in Lima, Peru	A retrospective, cohort, 3-month study was carried out during the period spanning from January 2012 to April 2013	136	Demented patients had costs of US\$ 1500 or over (and more than US\$ 1860 for frontotemporal dementia). The monthly cost of a demented patient (US\$ 570) was 2.5 times higher than the minimum wage (legal minimum monthly wage in Peru for 2011: US\$ 222.22).	--	Custodio et al. Dement Neuropsychol 2015; 9 (1): 32-41	--
Brazil (Sao Paulo)	Brain Bank from the Biobank for Aging Studies	Cross-sectional study	1200	Vascular dementia was common. Even few years of education were associated with lower dementia risk	--	1- Suemoto CK., et al. PLoS Med. 2017; 14:e1002267. 2- Farfel JM., et al.	--

						Neurology 2013; 81:650-7.	
Brazil (Tremembé)	Prevalence of Cognitive Impairment Without Dementia and Dementia in Tremembé, Brazil	Cross-sectional study	630	The prevalence of dementia in this study was higher than in other studies, particularly among younger elderly.	17.50	César KG., et al. Alzheimer Dis Assoc Disord. 2016 Jul-Sep; 30(3):264-71.	--
Brazil (Catanduva)	Epidemiologic Survey of Dementia in a Community-Dwelling Brazilian Population.	Cross-sectional study	1656	AD was the most frequent diagnosis. Age, female gender, and low educational level were significantly associated with a higher prevalence of dementia.	7.10	Herrera E. Jr., et al. Alzheimer Dis Assoc Disord. 2002 Apr-Jun; 16(2):103-8.	--
Brazil (São Paulo, Belo Horizonte, Porto Alegre, Salvador, Rio de Janeiro, and Vitória)	Brazilian Longitudinal of Adult Health (ELSA-Brasil)	Prospective cohort study	15105	The ELSA-Brasil investigated several risk factors related to cognitive performance, as subclinical atherosclerosis, inflammation, thyroid function, and postural hypotension	--	1- Suemoto CK., et al. Atherosclerosis 2015; 243:510-5. 2- Suemoto CK., et al. Int J Geriatr Psychiatry. 2017. 3- Suemoto CK., et al. J Gerontol A Biol Sci Med Sci. 2018. 4- Szejf C. et al. Psychoneuroendocrinology 2018; 87: 152-158. 5- Baena CP., et al. Exp Gerontol 2017; 92:82-86. 6- Cezaretto A., et al. Diabetol Metab Syndr. 2018; 10:54. 7- Pellegrino Baena C., et al. Cephalalgia 2018; 38:1525-1534.	--

Brazil (Caeté)	The Pietà Study	Cross-sectional study	639	Age, low education and previous history of depression were associated with dementia diagnoses. High prevalence of severe white matter lesions on MRI was observed and white matter lesions were associated with hypertension and cognitive status. Parkinsonism was identified in 10.7% of the population	27.50	1- Caramelli P., et al. Arq Neuropsiquiatr 2011; 69: 579-84. 2- Caramelli P., et al. Alzheimers Dementia 2009; 5 (Suppl.): 391-2. 3- Resende EPF., et al. eNeurologicalSci. 2016; 5:30-34. 4- Vale TC., et al. Parkinsonism Relat Disord 2018; 56:76-81. 5- Leles da Costa Dias F., et al. J Affect Disord 2019; 242:173-179.	--
Brazil (Catanduva)	Incidence of dementia in a community-dwelling Brazilian population	Prospective cohort study	1119 individuals were rescreened (3.25 years after previous study)	The prevalence rates of dementia almost doubled with every 5 years of age.	13.8 (per 1000)	Nitrini, R. et al. Alzheimer Dis. Assoc. Disord. 2004; 18, 241-246.	--
Uruguay, Perú, Chile, Brazil, Venezuela and Cuba	Prevalence of dementia in Latin America : a collaborative study of population-based cohorts	A collaborative study of population-based cohorts	31174	The global prevalence of dementia in LA proved similar to developed countries, although a higher prevalence of dementia in relatively young subjects was evidenced.	7.10	Nitrini R, et al. Int Psychogeriatr. 2009; 21(4): 622-30	--
Brazil (Piraju)	Identification of dementia cases in the community: a Brazilian experience	Community-based dementia case-finding method (cross-sectional study)	2222 participants above 65 years old	Most of the dementia cases correspond to Alzheimer's disease and vascular dementia	2	Ramos-Cerqueira, A., et al. J. Am. Geriatr. Soc. 2005; 53, 1738-1742.	--

Brazil (Sao Paulo)	Estimate of Dementia Prevalence in a Community Sample from São Paulo, Brazil	Cross-sectional study (A cluster random sampling of a population of individuals aged 60 years and over from three different socioeconomic classes (up- per, middle and low) was used)	1563 participants above 60 years old	Dementia prevalence was 12.9%, considering design effect, nonresponse during the community phase, and positive and negative predictive values. The most common cause of dementia was Alzheimer's disease, followed by vascular dementia.	6.80	Bottino, C. M. et al. Dementia and Geriatric Cognitive Disorders 2008; 26, 291–299	--
Peru, Mexico, China, and India, and in three urban sites in Cuba, the Dominican Republic, and Venezuela	Prevalence , Distribution , and Impact of Mild Cognitive Impairment in Latin America , China , and India : A 10 / 66 Population- Based Study	Data from the cross-sectional phase of the 10/66 Dementia Research Group (DRG) program on dementia (focused on MCI epidemiological research)	15376 > 65+ without dementia (approx. 2000 per country)	After direct standardization for age, gender and education level, MCI prevalence was = 1.5 for Cuba; 1.3 for Dominican Rep.; 2.6 for Perú; 1.0 for Venezuela, 2.8 for Mexico and 3.0 for Puerto Rico.	Cuba = 1.8; Dominican Rep. = 1.4; Peru = 3.1; Venezuela = 1.2; Mexico = 3.2; Puerto Rico = 3.9	Sosa AL, et al. PLoS medicine 2012; 9(2): e1001170	--
Cuba (Havana City and Matanza provinces)	The 10/66 study in Cuba	Cross-sectional door-to-door study	2944 participants above 60 years old	Dementia was the main cause of disability and dependency in the study population	10.80	Llibre Jde J, et al. MEDICC Rev 2011; 13(4):30-7	--
Chile	National Survey of Dependency (NSD) in the elderly (2010)	Cross-sectional survey, carried out in a probabilistic sample of independent-living older adults	4860 participants above 60 years old	--	7.00	SENAMA 2010. Estudio Nacional de la Dependencia en las Personas Mayores.	--
Venezuela (Caribbean coast)	Population-based Maracaibo Aging Study	Cross-sectional	2438 participants above 65 years old	The most frequent type of dementia was Alzheimer's disease, followed by vascular dementia.	8.04	Molero, A. E., et al. Neuroepidemiology 2007; 29, 107–112	

Uruguay	Prevalence of demential syndromes in a population of Uruguay: Study of 'Villa del Cerro'	Cross-sectional	--	--	4.03	Ketzoian C, et al., J Neurol Sci 1997; 150(suppl):155.	--
Cuba (Havana City municipality of Playa)	Prevalence of Dementia and Alzheimer's Disease in a Havana Municipality: A Community-Based Study among Elderly Residents	Cross-sectional	18351 participants above 65 years old	Alzheimer's disease was the most frequent cause of dementia, followed by mixed dementias. Risk factors associated with dementia were: history of stroke, hypertension, depression, skull-brain trauma, family history of dementia, low educational level and advanced age.	8.20	Llibre J., et al. MEDICC Rev 2009; 11(2):29-35.	--
Colombia (central, southwest, northwest, eastern, and Caribbean coast)	National Neuroepidemiological Study (EPINEURO)	Cross-sectional survey	8910	--	13.1 (per 1000)	Pradilla G., et al. Pan American Journal of Public Health 2003; 14, 104–111.	--
Brazil (Ribeirão Preto)	Prevalence of cognitive and functional impairment in a community sample in Ribeirão Preto, Brazil	Cross-sectional survey - Prevalence of cognitive and functional impairment (CFI)	1145 participants above 60 years old	CFI was associated with higher age, low education, stroke, epilepsy and depression.	18.9 for CFI	Lopes MA., et al. Int J Geriatr Psychiatry 2007; 22:770–76	--
Latin America (systematic review)	The global prevalence of dementia : A systematic review and meta-analysis	Systematic review and meta-analysis	135 publications (describing 147 studies) were fully eligible for inclusion in the review. Latin America (11 studies)	--	8.48(standardized prevalence)	Prince M, et al. Alzheimers Dement 2013;9(1):63-75.e2.	--
Latin America (systematic review)	Prevalence of dementia in the elderly in Latin America: A systematic review	Systematic review of the literature	357 publications	--	11	Zurique Sánchez C., et al. Rev Esp Geriatr Gerontol 2019.	--

Brazil (systematic review)	Reliability of Nationwide Prevalence Estimates of Dementia: A Critical Appraisal Based on Brazilian Surveys	Search of PubMed, Latin-American databases, and a Brazilian thesis database for surveys focusing on dementia prevalence in Brazil.	Six population-based surveys. All but one evaluated large samples (>1000) and half of the studies included only subjects aged 65 years and older	Dementia prevalence was 15.2% after adjustment for accuracy of screening tests.	7.10	Chaimowicz F., et al. PLoS One 2015; 10(7):e0131979	The systematic review was registered at PROSPERO (CR D42014008 815)
Cuba (La Habana and Matanzas)	Incidence of dementia and association with APOE genotype in older Cubans	Follow-up (average follow-up period of 4.5 years)	1892	Based on 10/66 dementia criteria, prevalence was of was 20.5 / 1000 whereas for DSM-IV dementia was 9.0/1000 person-years	20.5 (per 1000)	Rodríguez JLL., et al. Dement Neuropsychol 2014; 8(4):356-363	--
Brazil (Ribeirão Preto)	High prevalence of dementia in a community-based survey of older people from Brazil: association with intellectual activity rather than education	Cross-sectional and community-based survey	1145 participants above 60 years old	Alzheimer's disease was the main cause. Associated factor with dementia were: age, low education, stroke, absence of arthritis, and not reading books.	5.90	Lopes MA., et al. J Alzheimers Dis 2013; 32(2):307-16.	--
Colombia (Neiva)	Dementia prevalence in Neiva district	Cross-sectional	643 participants above 60 years old	Risk factors related to dementia prevalence were study level, harsh living conditions and some illnesses.	23.60	Gooding M., et al. Acta Neurol Colombiana 2006; 22:243-248	--
Cuba (Havana)	The Prevalence, Correlates and Impact of Dementia in Cuba	Population-based cross-sectional surveys	2944 participants above 65 years old	Dementia was associated with older age, less education, a family history of dementia, shorter leg length and smaller skull circumference.	10.80	Rodríguez JLL., et al., Neuroepidemiology 2008; 31(4):243-51	--
Mexico	Mexican Health and Aging Study and the The Cognitive Aging Ancillary Study (Mex-Cog)	Longitudinal study that examines the aging processes and its disease and disability burden in a large	7000/2700	Prevalence of 6.1% and 28.7% for dementia and cognitive impairment without dementia, respectively. Rates of dementia and cognitive impairment without dementia increased with advancing age and decreased with higher	6.10	Mejia-Arango S., et al. Aging Health 2011; 23(7):1050–1074.	--

		representative panel of older Mexican. A subsample is being assessed using a harmonized cognitive assessment protocol		educational level; sex had a differential effect depending on the age strata. Hypertension, diabetes, and depression were risk factors for dementia but not for cognitive impairment without dementia.			
Brazil (Porto Alegre)	Porto Alegre Longitudinal Aging study	Longitudinal study from a large university hospital catchment area	345 participants >60 years old at baseline - 7 PubMed publications	The MCI annual conversion rate to AD was 8.5%. MCI was associated with significantly higher risk of conversion to AD (HR = 49.83, p = 0.004), after adjustment for age, education, sex and Mini-Mental State Examination score.	--	--	--
Argentina (Buenos Aires)	Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients.	Prospective cohort study	358 elderly (>or= 65 years old) patients (239 with MCI and 119 with MBI) followed for up to 5 years until conversion to dementia or censoring.	34% of MCI patients and over 70% of patients with MBI developed dementia. MBI patients without cognitive symptoms were more likely to develop dementia. MBI patients were more likely to develop frontotemporal dementia (FTD) than dementia of the Alzheimer's type (DAT).	--	Taragano FE., et al. J Clin Psychiatry 2009; Apr; 70(4):584-92.	--
Argentina (Buenos Aires)	Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina.	Cross-sectional study	Eighty community-dwelling patients, 20 institutionalized AD patients and their respective primary caregivers, and 25 healthy elderly subjects participated in this study.	The annual direct costs of the disease increased with cognitive deterioration from US\$3420.40 in mild to US\$9657.60 in severe AD, and with institutionalization (US\$3189.20 outpatient vs. US\$14,447.68 institutionalized). Most direct costs were paid for by the family.	--	Allegri RF., et al. Int Psychogeriatr. 2007 Aug; 19(4):705-18.	--



Argentina (Buenos Aires)	A population-based study of cognitive impairment in socially vulnerable adults in Argentina. The Matanza Riachuelo study preliminary results.	Cross-sectional study	2437	The prevalence of CI among those over 60 was 26.4% (18.1% CIND and 8.3% dementia) with higher prevalence of dementia in younger individuals than rates reported in developed countries, probably due to low control of vascular risk factors.	--	Bartoloni L., et al. Dement Neuropsychol 2014; Oct-Dec;8(4):339-344.	--
Argentina (Buenos Aires)	Epidemiological study of dementia population in Argentina	Cross-sectional study	1453	Prevalence of 23% in cognitive impairment. Cognitive impairment was associated with age, low education, head trauma, hypertension and depression.	--	Arizaga, R. et al. (2019). Deterioro cognitivo en mayores de 60 años en Cañuelas (Argentina). Resultados del piloto del estudio Ceibo (Estudio Epidemiológico poblacional de demencia).	--
Brazil (Amazonas)	Cognitive impairment in individuals with lower educational level and homogeneous sociocultural background	Cross-sectional study	163 participants above 50 years old	Cognitive impairment was observed in 11.4%.	4.9 age > 50; and 12.3 age > 64	Brucki SMD. et al. Dement Neuropsychol 2014.	--
Brazil (Florianópolis)	Cognitive and functional impairment in an older community population from Brazil: The intriguing association with frequent pain	Cross-sectional study	1705 participants above 60 years old	Older age, presence of diabetes, heart disease, stroke, urinary incontinence, arthritis, frequent pain and depression were significantly associated with CFI.	19.20	Lopes MA., et al. Archives of Gerontology and Geriatrics 2016; v.66, p.134 - 139.	--
Brazil (Florianópolis)	Dementia in elderly inpatients admitted to medical wards in Brazil: diagnosis and comorbidity with other clinical diseases.	Cross sectional study (at General Hospital)	224 participants above 60 years old	Dementia was related to older age and the presence of delirium, stroke, and pneumonia.	17.20	Maia E., et al. Psychogeriatrics 2016; 16: 177–184	--

Brazil (Florianópolis)	Delirium in elderly inpatients admitted to clinical wards Prevalence and investigation of clinical conditions in a Brazilian sample.	Cross sectional study (at General Hospital)	173 participants above 60 years old	Delirium was directly associated with Urinary Tract Infection, Renal Failure and Dementia.	17.9	Pereira FDB., et al. Neuropsychologia 2018; v.12, p.152 – 156.	--
Brazil (Tremembé)	Incidence of Dementia and Mild Cognitive Impairment in a Brazilian population	Longitudinal Study (from Tremembé Epidemiological Study)	520	Ongoing	--	--	--
Costa Rica (Heredia)	Epidemiological Study of Cognitive Impairment of Older people in rural, urban, transition and outside regions Great Metropolitan Area in Costa Rica.	Descriptive observational study	Pilot study of 101 cases.	The average age of onset of memory problems was reported at 85 years in the case of the father, 87 years in the mother and 63 years in the case of siblings. 15.8% had a history of alcoholism.	--	--	--

## Annex 2. LAC clinical trials

ClinicalTrials.gov Identifier	Official Study title	Status	Study type	Countries	Representative Publications
NCT01574053	Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	Observational prospective	Argentina, Chile, Combia, other countries in North America, Europe and Oceania	Landwehrmeyer et al. Mov Disord Clin Pract. 2016 Jun 22; 4(2):212-224.
NCT01055392	Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease	Finished	Interventional, phase II, RCT	Brazil	1- Forlenza OV., et al. Br J Psychiatry 2019 Apr 5:1-7. 2- Aprahamian I., et al. J Clin Psychiatry 2014 Jul; 75(7):e672-8. 3- Forlenza OV., et al. Br J Psychiatry 2011 May; 198(5):351-6.
NCT01998841	A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort	Active, not recruiting	Interventional, phase II, RCT	Colombia	Tariot PN., et al. Alzheimers Dement (N Y) 2018; 4:150-60.
NCT02670083	CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)	Active, not recruiting	Interventional, phase III, RCT	Costa Rica , Perú, Brazil, Argentina	This study was discontinued by the sponsor (Hoffman-La Roche), due to efficacy issues.
NCT03443973	Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)	Recruiting	Interventional, phase III, RCT	Argentina, Chile, Mexico, Puerto Rico, other countries in North America, Europe and Asia	--
NCT01872598	Masitinib in Patients With Mild to Moderate Alzheimer's Disease	Active, no recruiting	Interventional, phase III, RCT	Argentina, Brasil, Perú, other countries in Europe	--
NCT01481558	Effects of a non-focal plasticity protocol on apathy in moderate Alzheimer's disease: a randomized, double-blind, sham-controlled trial.	Finished	Interventional, phase III, RCT	Brazil	Suemoto CK, et al. Brain Stimul. 2014 Mar-Apr; 7(2):308-13.
NCT00623103	Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)	Finished	Interventional, phase III RCT: to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD	Argentina, other countries in North America and Europe	--

NCT00322153	A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type	Finished	Interventional, phase III RCT: To evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).	Argentina, Mexico, other countries in North America, Europe, Asia and Oceania	--
NCT01760005	A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease	Active, no recruiting	Interventional, phase II/III, RCT: to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.	Argentina, Brazil, Colombia, Mexico, Puerto Rico, other countries in North America, Europe, Asia and Oceania	1- Bateman RJ., et al N Engl J Med 2012 Aug 30; 367(9):795-804. Erratum in: N Engl J Med. 2012 Aug 23; 367(8):780. 2- Farlow M. et al. Alzheimers Dement. 2012 Jul; 8(4):261-71.
NCT01295957	Phase 4 Study of a Reminiscence Program to Improve Quality of Life of Alzheimer's Disease Long Term Care Residents Using a Randomized Controlled Trial	Finished	Interventional, phase IV, RCT	Argentina	--
NCT02585934	A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease	Finished	Interventional, phase III, RCT: to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.	Argentina, Chile, other countries in North America, Europe, Asia and Oceania	--
NCT02956486	A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease	Recruiting	Interventional, phase III, RCT	Argentina, other countries in North America, Europe, Asia and Oceania	--
NCT01799915	Natural History Study of Synucleinopathies	Recruiting	Observational, prospective	Argentina, other countries in North America, Europe and Asia	--

NCT03443973	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease	Recruiting	Interventional, phase III, RCT	Argentina, Chile, Mexico, Puerto Rico, other countries in North America, Europe and Asia	--
NCT03131453	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).	Recruiting	Interventional, phase III/III, RCT	Argentina, Chile, Mexico, Puerto Rico, other countries in North America, Europe, Asia, Africa and Oceania	--
NCT02586909	A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease	Terminated (Intepirdine did not meet its primary efficacy endpoints in lead-in study RVT-101-3001.)	Interventional, phase III, single group assignment	Argentina, Chile, other countries in North America, Europe, Asia and Oceania	--
NCT02079246	An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease	Finished	Interventional, phase III, non-randomized	Argentina, Brazil, Chile, other countries in North America, Europe, Asia and Africa	--
NCT02006641	Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil	Finished	Interventional, phase III, RCT	Argentina, Brazil, other countries in North America, Europe and Asia	1- Cummings JL., et al. Alzheimers Res Ther. 2018 Nov 24; 10(1):116. 2- Atri A., et al. JAMA 2018 Jan 9; 319(2):130-142.
NCT01955161	Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil	Finished	Interventional, phase III, RCT	Argentina, Brazil, other countries in North America, Europe and Asia	1- Cummings JL., et al. Alzheimers Res Ther. 2018 Nov 24; 10(1):116. 2- Atri A., et al. JAMA 2018 Jan 9; 319(2):130-142.
NCT01224106	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment	Active, no recruiting	Interventional, phase III, RCT	Argentina, Brazil, Chile, Mexico, other countries in North America, Europe, Asia and Oceania	1- Ostrowitzki S., et al. Alzheimers Res Ther. 2017 Dec 8; 9(1):95. Erratum in: Alzheimers Res Ther. 2018 Sep 27; 10(1):99. 2- Delrieu J., et al. Expert Opin Biol Ther 2012 Aug; 12(8):1077-86.
NCT03114657	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease	Active, no recruiting	Interventional, phase III, RCT	Argentina, Brazil, Perú, other countries in North America, Europe, Asia, Africa and Oceania.	--

NCT01127633	Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid $\beta$ Antibody in Patients With Alzheimer's Disease	Terminated (Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.)	Interventional, phase III, RCT	Argentina, Brazil, other countries in North America, Europe, Asia.	--
NCT00905372	Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo	Finished	Interventional, phase III, RCT	Argentina, Brazil, other countries in North America, Asia.	1- Reed C., et al. <i>Alzheimers Res Ther.</i> 2018 Apr 3; 10(1):36. 2- Liu-Seifert H., et al. <i>J Alzheimers Dis.</i> 2015; 47(1):205-14. 3- Henley DB., et al. <i>Alzheimers Res Ther.</i> 2015 Jun 25; 7(1):43. 4- Liu-Seifert H., et al. <i>J Alzheimers Dis.</i> 2015; 43(3):949-55. 5- Doody RS., et al. <i>N Engl J Med.</i> 2014 Jan 23; 370(4):311-21.
NCT00710684	Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease	Finished	Interventional, phase II, RCT	Argentina, Chile, other countries in North America, Europe, Oceania.	Maher-Edwards G., et al., <i>Alzheimers Dement (N Y)</i> . 2015 May 7; 1(1):23-36.
NCT00490568	An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.	Terminated (Based on preliminary parent study results)	Interventional, phase III, single group assignment	Argentina, Chile, Mexico, other countries in North America, Africa, Asia, Europe, Oceania.	Harrington C., et al. <i>Curr Alzheimer Res.</i> 2011 Aug; 8(5):592-606.
NCT00348309	A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE $\epsilon$ 4-stratified Subjects With Mild to Moderate Alzheimer's Disease.	Finished	Interventional, RCT	Argentina, Brazil, Chile, Mexico, other countries in North America, Asia, Europe.	Harrington C., et al. <i>Curr Alzheimer Res.</i> 2011 Aug; 8(5):592-606.
NCT00277810	A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor	Finished	Interventional, phase II/III, RCT	Argentina, other countries in North America, Africa, Europe, Oceania.	--
NCT00151398	A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.	Finished	Interventional, phase II, RCT	Argentina, Australia, Canada, South Africa, United States	--

NCT00895895	A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease	Terminated (all of the 3 SAM-531 dosage levels were declared futile)	Interventional, phase II, RCT	Argentina, Chile, Colombia, Mexico, other countries in North America, Asia, Europe, Oceania.	--
NCT00884507	A Dose-ranging, Randomized, Double-blind, Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease	Finished	Interventional, phase II, parallel assignment	Argentina, Mexico, other countries in North America, Europe, Oceania.	--
NCT00676143	A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers	Terminated (2 large Phase 3 studies showed no clinical benefit)	Interventional, phase III, RCT	Argentina, Chile, Mexico, other countries in North America, Europe, Africa, Oceania.	1- Vandenberghe R. et al. Alzheimers Res Ther. 2016 May 12; 8(1):18. 2- Lacey L., et al. Value Health. 2015 Jul; 18(5):638-45. 3- Doody RS., et al. N Engl J Med. 2013 Jul 25; 369(4):341-50. 4- Liu-Seifert H., et al. J Alzheimers Dis. 2015; 47(1):205-14. 5- Doody RS., et al. Alzheimers Res Ther. 2015 Jun 10; 7(1):36. 6. Henley DB., et al. Alzheimers Res Ther. 2015 Jun 25;7(1):43.
NCT00594568	Effect of $\gamma$ -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo	Finished	Interventional, phase III, RCT	Argentina, Chile, other countries in North America, Europe, Africa, Asia, Oceania.	----
NCT02051608	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients	Active, no recruiting	Interventional, phase III, RCT	Argentina, Guatemala, other countries in North America, Europe, Asia, Oceania.	--
NCT00667810	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers	Terminated (2 large Phase 3 studies showed no clinical benefit)	Interventional, phase III, RCT	Argentina, Chile, Mexico, other countries in North America, Europe, Africa, Asia, Oceania.	1- Vandenberghe R., et al. Alzheimers Res Ther. 2016 May 12; 8(1):18. 2- Lacey L., et al. Value Health. 2015 Jul; 18(5):638-45.
NCT00297414	An Analysis of Mortality in Subjects Who Participated in Three Studies of Galantamine in Mild Cognitive Impairment	Finished	Observational, retrospective	Argentina, other countries in North America, Europe, Asia, Oceania.	--
NCT00998764	A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.	Terminated (2 large Phase 3 studies showed no clinical benefit)	Interventional, phase III, non-randomized	Argentina, Chile, other countries in North America, Europe, Africa, Asia, Oceania.	Ivanou A., et al. Alzheimers Res Ther. 2016 Jun 23;8(1):24.

		benefit)			
NCT00869817	Dominantly Inherited Alzheimer Network (DIAN)	Recruiting	Observational, prospective	Argentina, other countries in North America, Europe, Asia, Oceania.	1- Mintun MA., et al. Neurology. 2006 Aug 8; 67(3):446-52. 2- Fagan AM., et al. Arch Neurol. 2007 Mar; 64(3):343-9. 3- Godbolt AK., et al. Neurocase. 2005 Feb; 11(1):56-64. 4- Morris JC., et al. Neurology. 1991 Apr; 41(4):469-78. 5- Galvin JE., et al Arch Neurol. 2005 May; 62(5):758-65. 6- Gordon BA., et al Lancet Neurol. 2018 Mar; 17(3):241-250. 7- Bateman RJ., et al. N Engl J Med. 2012 Aug 30; 367(9):795-804. Erratum in: N Engl J Med. 2012 Aug 23; 367(8):780.
NCT01574053	Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort	Recruiting	Observational, prospective	Argentina, Chile, other countries in North America, Europe, Oceania.	Landwehrmeyer GB., et al. Mov Disord Clin Pract. 2016 Jun 22; 4(2):212-224.
NCT03260608	Randomized Clinical Assessment to Evaluate the Effectiveness of a Psychoeducation and Support Protocol by Telephone, in the Aid of Caregivers of Patients With Dementia in Specialized Ambulatory Accompanying	Recruiting	Interventional, RCT	Brazil	--
NCT01481558	Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's: a Randomized, Sham-controlled Clinical Trial	Finished	Interventional, phase II, RCT	Brazil	1- Suemoto CK., et al. Brain Stimul. 2014 Mar-Apr; 7(2):308-13. 2- Robertson K., et al. Clin Infect Dis. 2012 Sep; 55(6):868-76. 3- Albright AV., et al. J Neurovirol. 2003 Apr; 9(2):222-7. 4- McArthur JC., et al. J Neurovirol. 2003 Apr; 9(2):205-21. 5- Sacktor N. J Neurovirol. 2002 Dec; 8 Suppl 2:115-21.
NCT02222181	Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease	Finished	Interventional, single-group assignment	Brazil	--
NCT03075241	Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study	Recruiting	Interventional, phase III, RCT	Brazil	--
NCT01515982	Physical Exercise as an Additional Treatment for Alzheimer Disease	Finished	Interventional, RCT	Brazil	--
NCT00480870	The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients	Finished	Interventional, phase IV, RCT	Brazil	1- Strand LM., et al. Drug Intell Clin Pharm. 1988 Jan; 22(1):63-7. 2- Lanctôt KL., et al. CMAJ. 2003 Sep 16; 169(6):557-64. 3- Arlt S., et al. Drugs Aging. 2008; 25(12):1033-47. 4- Rosa A., et al. Cell Mol Life Sci. 2007 May; 64(10):1244-53. 5- Moraes W., et al. Chest. 2008 Mar; 133(3):677-83. 6- Lucchesi LM., et al. Braz J Psychiatry. 2005 May; 27 Suppl 1:27-32. 7- Moraes Wdos S., et al. Sleep. 2006 Feb; 29(2):199-205.
NCT01142258	Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study	Finished	Interventional, phase III, RCT	Brazil	Camargos EF., et al. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1565-74.



	Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease	Recruiting	Interventional, phase II, RCT	Brazil	1- Weiss A., et al. J Clin Invest. 2012 Oct; 122(10):3731-6. 2- Aleynik A., et al. Clin Transl Med. 2014 Jul 19; 3: 24. 3- de Almeida FM., et al. J Neurotrauma. 2011 Sep; 28(9):1939-49. 4- Barker RA., et al. J Neurol Neurosurg Psychiatry. 2013 Jun; 84(6):657-65. 5- Bonelli RM., et al. Curr Pharm Des. 2006; 12(21):2701-20. 6- de Souza PV., et al. Anat Rec (Hoboken). 2013 Dec; 296(12):1923-8. 7- Fink KD., et al. Regen Med. 2015; 10(5):623-46. 8- Kerkis I., et al. Tissue Eng Part B Rev. 2012 Apr; 18(2):129-38. 9- Ross CA., et al. Nat Rev Neurol. 2014 Apr; 10(4):204-16. 10- Kaplan A., et al. Prog Neurobiol. 2012 Dec; 99(3):262-80.
NCT02728115	First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease	Active, no recruiting	Interventional, phase I, non-randomized	Brazil	1- Adam OR., et al. Neurotherapeutics. 2008 Apr; 5(2):181-97. 2- Aleynik A., et al. Clin Transl Med. 2014 Jul 19; 3:24. 3- de Almeida FM., et al. J Neurotrauma. 2011 Sep; 28(9):1939-49. 4- Bachoud-Lévi AC., et al. Lancet Neurol. 2006 Apr; 5(4):303-9. 5- Bachoud-Lévi AC., et al. Lancet. 2000 Dec 9; 356(9246): 1975-9. 6- Ball LM., et al. Br J Haematol. 2013 Nov; 163(4):501-9. 7- Barker RA., et al. J Neurol Neurosurg Psychiatry. 2013 Jun; 84(6):657-65.
NCT03252535	Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease	Recruiting	Interventional, phase II, RCT	Brazil	1- Aleynik A., et al. Clin Transl Med. 2014 Jul 19; 3:24. 2- Aleynik A., et al. Clin Transl Med. 2014 Jul 19; 3:24. 3- de Almeida FM., et al. J Neurotrauma. 2011 Sep;28(9):1939-49. 4- Barker RA., et al. J Neurol Neurosurg Psychiatry. 2013 Jun; 84(6):657-65. 5- Bonelli RM., et al. Curr Pharm Des. 2006; 12(21):2701-20. 6- de Souza PV., et al. Anat Rec (Hoboken). 2013 Dec; 296(12):1923-8. 7- Fink KD., et al. Regen Med. 2015; 10(5):623-46. 8- Kerkis I., et al. Tissue Eng Part B Rev. 2012 Apr; 18(2):129-38. 9- Ross CA., et al. Nat Rev Neurol. 2014 Apr; 10(4):204-16. 10- Kaplan A., et al. Prog Neurobiol. 2012 Dec; 99(3):262-80. 11- Weiss A., et al. J Clin Invest. 2012 Oct; 122(10):3731-6.
NCT01183806	Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients	Finished	Interventional, phase III, RCT	Brazil	Aguiar P., et al. Curr Alzheimer Res. 2014; 11(6):532-7.
NCT01978353	Episodic Memory Training for Face Name Association in Patients With Amnesic Mild Cognitive Impairment: Cognitive Measures and Functional Resonance Magnetic Imaging	Finished	Interventional, RCT	Brazil	--

	Outcomes				
NCT01286389	Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition	Finished	Interventional, RCT	Brazil	--
NCT02626572	Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.	Finished	Interventional, phase II, RCT	Brazil, Chile, Mexico, Africa, Europe.	--
NCT03444870	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease	Recruiting	Interventional, phase III, RCT	Brazil, Colombia, Peru, other countries in North America, Asia, Europe, Oceania.	--
NCT02006654	Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor	Finished	Interventional, phase III, RCT	Brazil, Mexico, other countries in North America, Asia, Europe, Oceania.	1- Cummings JL., et al. Alzheimers Res Ther. 2018 Nov 24; 10(1):116. 2- Atri A., et al. JAMA. 2018 Jan 9; 319(2):130-142.
NCT00762411	Effect of LY450139 a $\gamma$ -Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo	Finished	Interventional, phase III, RCT	Brazil, Mexico, other countries in North America, Asia, Europe.	1- Liu-Seifert H., et al. J Alzheimers Dis. 2015; 47(1):205-14 2- Henley DB., et al. Alzheimers Res Ther. 2015 Jun 25; 7(1):43.
NCT03325556	A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis	Recruiting	Interventional, phase III, RCT	Chile, other countries in North America, Europe.	--
NCT00322153	A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type	Finished	Interventional, phase III, RCT	Argentina, Chile, Mexico, other countries in North America.	--
NCT00099242	Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease	Finished	Interventional, phase III, RCT	Chile, Guatemala, Mexico, Peru, Puerto Rico, Venezuela, other countries in North America, Asia, Europe.	Lefèvre G., et al. Int J Geriatr Psychiatry. 2011 Apr; 26(4):356-63.
NCT00954590	CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease	Finished	Interventional, phase III, RCT	Chile, Europe.	--
NCT02585934	A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease	Finished	Interventional, phase III, RCT	Argentina, Chile, other countries in North America, Asia, Europe, Oceania.	--

NCT03036280	A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease	Recruiting	Interventional, phase III, RCT	Chile, Mexico, other countries in North America, Asia, Europe, Asia, Africa, Europe.	--
NCT00930059	A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, other countries in North America, Europe.	--
NCT02992132	A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, other countries in North America, Europe.	--
NCT00708552	Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, Mexico, other countries in Europe, Asia and Africa	Maher-Edwards G., et al. Alzheimers Dement (N Y). 2015 May 7; 1(1):23-36.
NCT00428090	A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)	Finished	Interventional, phase III, RCT	Chile, Mexico, Peru, Puerto Rico, other countries in North America, Asia, Europe, Oceania.	Gold M., et al. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
NCT03118947	A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, other countries in North America, Europe.	--
NCT01009255	A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.	Finished	Interventional, phase II, RCT	Chile, Asia, Europe.	--
NCT01712074	A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil	Terminated	Interventional, phase II, RCT	Chile, other countries of North America, Europe.	Fullerton T., et al. Alzheimers Res Ther. 2018 Apr 5; 10(1):38.
NCT01035138	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment	Active, no recruiting	Interventional, phase III, RCT	Chile, other countries of North America, Asia, Africa, Europe, Oceania.	--
NCT00550420	An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.	Terminated (Based on preliminary parent study results)	Interventional, phase III, RCT	Chile, Mexico, Peru, Puerto Rico, Mexico, other countries in North America, Europe and Asia	Gold M., et al. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.

NCT00348192	A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, and other countries in Europe	Maher-Edwards G., et al. Int J Geriatr Psychiatry. 2011 May; 26(5):536-44.
NCT00224497	A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease	Finished	Interventional, phase II, RCT	Chile, other countries in Europe, Africa and Asia	--
NCT00996918	A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000	Terminated (2 large Phase 3 studies showed no clinical benefit)	Interventional, phase III, RCT	Chile, other countries in North America, Europe, Asia, Africa and Oceania	Ivanou A., et al. Alzheimers Res Ther. 2016 Jun 23; 8(1):24.
NCT01998841	A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease	Active, no recruiting	Interventional, phase II, RCT	Colombia	--
NCT02670083	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease	Active, no recruiting	Interventional, phase III, RCT	Costa Rica, Mexico, other countries in North America, Europe, Asia and Oceania	--
NCT02569398	A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia	Finished	Interventional, phase II/III, RCT	Mexico, other countries in North America, Europe, Asia and Oceania	--
NCT02783573	A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia	Terminated (An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion)	Interventional, phase III, RCT	Mexico, other countries in North America, Europe and Asia	Cebers G., et al. J Alzheimers Dis. 2017; 55(3):1039-1053.

NCT01969123	A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication	Terminated (Study has been suspended due to clinical hold)	Interventional, phase III, RCT	Mexico, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, South Africa, Spain, United States	--
NCT02537626	An Evaluation of the Effect of the Erchonia ALS on Alzheimer's Disease	Not yet recruiting	Interventional, RCT	Mexico	--
NCT03491150	A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease	Active, no recruiting	Interventional, phase III, single group assignment	Mexico, other countries in North America, Europe, Asia and Oceania	--
NCT03906903	Transcranial Magnetic Stimulation and Cognitive Stimulation in Mild Cognitive Impairment	Recruiting	Interventional, RCT	Mexico	--
NCT03036280	A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ (MissionAD2)	Recruiting	Interventional, phase III, RCT	Chile, Mexico, other countries in North America, Europe and Asia	--
NCT01024660	A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks	Finished	Interventional, early phase I, RCT	Peru, other countries in North America, Europe and Africa	Karin A., et al. Acta Neurol Scand. 2014 Feb; 129(2):114-22.
NCT03305809	Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Recruiting	Interventional, phase II, RCT	Puerto Rico, other countries in North America	--
NCT00948766	A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitIOn in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44	Finished	Interventional, phase IV, RCT	Puerto Rico, United States	Grossberg GT., et al. Curr Alzheimer Res. 2015; 12(1):53-60.
NCT02972658	A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)	Terminated (An independent assessment concluded the trial was not likely to meet the primary endpoint upon	Interventional, phase III, RCT	Puerto Rico, other countries in North America, Europe, Asia and Oceania	--

		completion)			
NCT02245737	A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)	Terminated (An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion)	Interventional, phase II/III, RCT	Puerto Rico, other countries in North America, Europe, Asia and Oceania	Cebers G., et al. J Alzheimers Dis. 2017; 55(3):1039-1053.
NCT02760602	A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease	Terminated (Insufficient scientific evidence that solanezumab)	Interventional, phase III, RCT	Puerto Rico, other countries in North America, Europe and Asia	--
NCT00838110	A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease	Finished	Interventional, phase III, RCT	Puerto Rico, other countries in North America	--
NCT00939783	An Open Label Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon (PF 01913539) In Patients With Alzheimer's Disease	Terminated (as part of modification of the dimebon development plan)	Interventional, phase III, non-randomized	Puerto Rico, other countries in North America	--
NCT00040378	Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)	Finished	Observational, prospective	Puerto Rico, Canada, United States	1- Lovell MA., et al. Neurology. 1995 Aug; 45(8):1594-601. 2- Sano M., et al. N Engl J Med. 1997 Apr 24; 336(17):1216-22. 3- Markesbery WR., et al. Brain Pathol. 1999 Jan 9(1):133-46 .4- Goodman PJ., et al. Trials. 2016 Aug 12; 17: 400. 5- Mathews M., et al. Curr Alzheimer Res. 2013 Sep; 10(7):776-83. 6- Kryscio RJ., et al. J Nutr Health Aging. 2013 Jan; 17(1):72-5. 7- Abner EL., et al. Trials. 2012 Nov 20; 13:217. 8- Caban-Holt A., et al. Clin Neuropsychol. 2012; 26(5):751-68. 10- Ding X., et al. J Am Geriatr Soc. 2016 Dec; 64(12):2472-2478. 11- Abner EL., et al. J Prev Alzheimers Dis. 2015 Mar; 2(1):11-16. 12- Kryscio RJ., et al. JAMA Neurol. 2017 May 1; 74(5):567-573.

NCT00235716	A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)	Finished	Interventional, phase III, RCT	Puerto Rico, United States	1- Dysken MW., et al. Alzheimers Dement. 2014 Jan; 10(1):36-44. 2- Dysken MW., et al. JAMA. 2014 Jan 1; 311 (1):33-44.
NCT02187276	The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia	Finished	Observational, prospective	Brazil	Miranda LF., et al. J Alzheimers Dis. 2015; 45(2):609-20.
NCT03349320	Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms	Finished	Observational, prospective	Brazil	Miranda LF., et al. J Alzheimers Dis. 2017; 55(2):539-549.
NCT01994265	Cognitive Impairment Related to Atrial Fibrillation Prevention Trial	Active, not recruiting	Interventional, phase IV, RCT	Brazil	Toledo ASF., et al. Int J Clin Trials. 2015; 2(4): 102-107
NCT03644290	Cognitive Training in Stroke Patients	Active	Interventional, RCT, non-pharmacological	Brazil, United Sates	1- Miotto EC., et al. NeuroRehabilitation. 2012; 31(4):463-4. 2- Batista AX., et al., Cortex 2019, vol. 113, pp. 15–28. 3- Batista AX., et al. Neural Plasticity Research 2019; Article (16 pages), Article ID 4172569. 4- Campanholo KR., et al. Behav Neurol. 2015
NCT03263247	Cognitive Training in Patients With MCI Using fMRI	Active	Interventional, RCT, non-pharmacological	Brazil, United Sates	1- Miotto EC., et al. Neural Plasticity 2018. Volume 2018, Article ID 7301530. 2- Balardin JB., et al. Front Aging Neurosci. 2015 Aug 4; 7:147. 3- Serrao VT., et al Dement Neuropsychol. 2015 Jul-Sep; 9(3):265-269. 4- Miotto EC., et al. Arq Neuropsiquiatr. 2014 Sep; 72(9):663-70. 5- Miotto EC., et al. Int Psychogeriatr. 2013 Jul; 25(7):1203-4. 6- Miotto EC., et al. Dement Neuropsychol. 2008 Apr-Jun; 2(2):139-145. 7- Fonseca LM., et al. Dement Geriatr Cogn Dis Extra. 2015 Sep 18; 5(3):330-40.
NCT00406588	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuation	Completed	Interventional, Phase III, RCT	Brazil, Colombia, Chile, other countries in North America and Europe	Rascol O.,et al. Parkinsonism Relat Disord. 2012 May; 18(4):370-6.
NCT01978353	Memory Strategy Training for Face Name Associations in the Amnesic Mild Cognitive Impairment: Cognitive and Magnetic Resonance Imaging Outcomes	Finished	Interventional, RCT, non-pharmacological	Brazil, United Sates	1- Simon SS., et al. Frontiers of Aging Neuroscience 2018. 2- Simon SS., et al. International Journal of Psychophysiology 2019.
NCT03911765	Effect of Digital Cognitive Training on the Functionality of Older Adults With Mild Cognitive Impairment (MCI)	Recruiting	Interventional, Phase I RCT, crossover assignment	Brazil	--
NCT01286389	Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition	Completed	Interventional (Clinical Trial)	Brazil	--
NCT02121457	Brazil Nuts Effects on Selenium Status and Cognitive Performance	Completed	Interventional	Brazil	--
NCT01142258	Trazodone for Sleep Disorders in Alzheimer's Disease	Completed	Intervention, phase III	Brazil	--

NCT01481558	Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease	Completed	Intervention, Parallel Assignment	Brazil	Suemoto CK., et al. Brain Stimul. 2014 Mar-Apr; 7(2):308-13.
NCT03260608	Effectiveness of a Psychoeducation and Support Protocol by Phone in the Aid of Caregivers of Patients With Dementia.	Recruiting	Interventional, RCT, non-pharmacological	Brazil	--



### Annex 3: Local and regional research initiatives

Countries involved	Source	Title	Study type	Number and type of participants	Status	Representative Publications	Other information
Argentina, Brazil, Puerto Rico	Alzheimer's Association	Alzheimer's Disease Neuroimaging Initiative	Cognition, imaging and genetics	>1000, including AD, MCI and controls	Ongoing	Carrillo et al. Alzheimers Dement. 2012 Jul; 8(4):337-42.	Ongoing plans to include Colombia and Mexico
Argentina, Brazil, Chile, Colombia, Mexico, Peru	Alzheimer's Association Tau Consortium GBHI NIH NIA	Multi-partner consortium to expand dementia research in Latin America	Comparison of genetics, imaging and cognition in US vs Latin American samples of AD, FTD and controls	4200 participants (1050 AD, 1050 FTD, 2100 controls)	To initiate	--	--
Argentina, Brazil, Colombia, Peru	NIH R01 AG057234	US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative Research	Comparison of genetics, imaging and cognition in US vs South American samples of AD, FTD and controls	3000 participants (750 AD, 750 FTD, 1500 controls)	To initiate	--	--
Chile	National Fund for Scientific and Technological Development (FONDECYT) # 11100457	The needs of people with dementia and its relationship with personal, social and caregivers' factors.	Cross-sectional survey to identify PWD's met and unmet needs	166 dyads of people with dementia and their informal caregivers	Finished	1- Tapia Muñoz, T., et al. BMC Geriatrics 2019; 19, 106. 2- León-Campos, MO., et al. Ansiedad y Estrés 2018; 24(2-3), 73-80.	--
Chile	National Fund for Scientific and Technological Development (FONDECYT) # 1141279	Implementation and effectiveness of an evidence-based psychoeducational program in a group of family caregivers of people with dementia.	RCT Psychosocial intervention for family caregivers of PWD	91 family caregivers of PWD	Finished	--	--
Chile	National Fund for Scientific and Technological Development (FONDECYT) # 1191726	Trajectories and predictors of depression and anxiety symptoms in family caregivers of PWD: a longitudinal study	Cohort, observational	250 dyads of people with dementia and their family caregivers	To initiate	--	--
Chile	Research Fund, University of Valparaíso, N° 08/2009	"Adaptation, pilot and effectiveness of a Cognitive Stimulation Program in a group of older people with Alzheimer's Disease.	Pilot RCT Cognitive Stimulation Therapy	22 institutionalised persons with dementia	Finished	Miranda-Castillo, C. et al. Universitas Psychologica 2013. 12. 445-456.	--
Argentina, Chile	PICT Grant, FONCYT, Argentina	Neurocognitive and translational neuromarkers for neurodegenerative disorders: An ecological approach based on	Cognition, imaging	>100, including, AD, PD, FTD, stroke, ataxia, multiple sclerosis, controls	Ongoing	Salamone, PC., et al. Human Brain Mapping 2018; Dec;39(12):4743-4754.	Ongoing plans to include Uruguay

		socio-emotional processing and language embodiment					
Argentina, Chile	PICT Grant, FONCYT, Argentina	The cognitive impact of non-invasive brain stimulation combined with behavioral training: memory and language in patients with mild cognitive impairment and early Parkinson's disease	--	>100, including, AD, MCI, PD, and controls	Ongoing	--	--
Argentina	SGCTIP-FONARSEC (PBIT/09), Argentina	Translational Medicine Program for Innovations in Research, Diagnosis and Treatment of Alzheimer's Disease	Cognition, biomarkers and genetics	>1000, including AD, MCI and controls	Ongoing	Dalmaso et al. Translational Psychiatry 2019; 9:55.	--
Argentina	FONCyT-PICT2015-0285, Argentina	Neo-angiogenesis and Bioenergetics: new paradigms for the search of biomarkers with prognostic value in Alzheimer's disease	Cognition, biomarkers and genetics	25 cases and 25 controls	Ongoing	--	--
Argentina	FONCyT-PICT Start up (PICT-2016-4647), Argentina	TARGET-AD: a clinical algorithm that considers the risk of Alzheimer's disease through the use of genetic variants and their interaction with environmental factors	--	>1000, including AD, MCI and controls	Ongoing	--	Ongoing plans to include Uruguay
Argentina, Chile, Uruguay, Spain, Portugal and Germany	EU-LAC Health-Neurodegeneration JOINT CALL 2016-2017	HIGH FAT DIET, MICROBIOTA AND NEUROINFLAMMATION IN THE PROGRESSION OF ALZHEIMER DISEASE	cognition, genetic, diet	25 cases and 25 controls	Ongoing	--	--
Brazil	FAPESP - The State of São Paulo Research Foundation (grants #2015/10109-5 & #2015/18125-0)	Comparative analysis of cerebrospinal fluid and serum markers in dementia with Lewy Bodies and Alzheimer's Disease dementia	cross-sectional	54 patients and 27 controls	Ongoing	Representation in the Executive Committee of the ISTAART Biofluid Based Biomarkers Professional Interest Area.	Available at <a href="https://bv.fapesp.br/en/bolsas/161804/comparative-analysis-of-cerebrospinal-fluid-and-serum-markers-in-dementia-with-lewy-bodies-and-alzhe/">https://bv.fapesp.br/en/bolsas/161804/comparative-analysis-of-cerebrospinal-fluid-and-serum-markers-in-dementia-with-lewy-bodies-and-alzhe/</a> or at <a href="https://grants.ube.br/research.com/501100001807/15%252F18125-0/Comparative-analysis-of-cerebrospinal-fluid-and-serum-">https://grants.ube.br/research.com/501100001807/15%252F18125-0/Comparative-analysis-of-cerebrospinal-fluid-and-serum-</a>

							markers-in-dementia-with-Lewy-Bodies-and-Alzheimers-Disease-dementia.
Brazil	FAPESP Grant 13/01758-4	Research of GRN and MAPT mutations and plasma progranulin dosage in Brazilian patients from patients with frontotemporal lobar degeneration	--	--	--	--	--
Peru	National fund for scientific, technological and innovation development (FONDECYT) # 103-2018 FONDECYT	Identification of altered brain connectivity patterns as a cognitive biomarker in pre-clinical phases of dementia using low density EEG	Cognition, EEG biomarkers	>140, including SCD, MCI, AD and controls	Ongoing	--	--
Peru	Research Fund, Universidad Nacional de San Agustín, # IAI-007-2018-UNSA	Effects of cognitive training on brain processing networks in older people with subjective cognitive decline	Non-pharmacological intervention, EEG functional connectivity	> 60, including SCD and controls	Ongoing	--	--
Chile	Primer Concurso Idea en dos etapas temático en Adulto Mayor Fomento al Desarrollo Científico y Tecnológico-Fondef de Conicyt FONDEF # ID16AM0046 (2016-2018) Plataforma informática de análisis de variables médicas y psico-sociales para la caracterización, categorización y monitoreo de adultos mayores con enfermedades cerebrales : Una experiencia demostrativa en la	Plataforma informática de análisis de variables médicas y psico-sociales para la caracterización, categorización y monitoreo de adultos mayores con enfermedades cerebrales : Una experiencia demostrativa en la región de Aysén.	Cross-sectional survey	80 elderly living at the community	Finished	In preparation	--

	región de Aysén.						
Chile	Fondap N° 15150012 (2016-2020)	Geroscience Center for brain Health and Metabolism.	Longitudinal study	150 (expect inclusion: 300) with SCD and MCI. Ongoing.	Ongoing	Thumala D., et al. Health Syst Reform 2017; 3(4):253-260.	--
Chile	Fondecyt # 1160940 (2016- 2019)	Social cognition in the amyotrophic lateral sclerosis and frontotemporal dementia continuum.	Cross-sectional clinical study . Cognition and Neuroimaging	15 FTD patients, 20 ALS and 20 controls	Finished	Lillo P., et al. Revista Médica de Chile 2014; 142: 867-879	--
Chile	Fondecyt # 1140423 (2014-2016)	Physiopathology of Apathy in Alzheimer's Disease: A neuropsychological and neuroimaging study	Cross-sectional clinical study . Cognition and Neuroimaging	40 patients with Alzheimer's disease dementia and 40 healthy brain controls	Finished	1- Slachevsky A., et al. Journal of Neurology 2019; 1–13. 2- Delgado C., et al. J Alzheimers Dis. 2019; 67(1):381-392.	--
Chile	Fondecyt # 1140114 (2014-2016)	Fluid intelligence, social cognition and perspective change as predictors of psychosocial adaptability	--	--	--	--	--
Chile	Fondecyt (2009-2012) 1100975	Validation of Neuropsychological Tests and Biomarkers For The Diagnosis Of Mild Alzheimer Disease.	Cross-sectional clinical study. Cognition and Neuroimaging	30 patients with Alzheimer's disease dementia and 30 healthy brain controls	Finished	1- Slachevsky A., et al. J Alzheimers Dis. 2018; 62(4):1887-1900. 2- Slachevsky A., et al. Journal of Alzheimer's Disease 2017; 55(4):1595-1603. 3- Delgado C., et al. Archives of Clinical Neuropsychology 2016; 31(2):165-75	--
Chile	Cuarto Concurso de Proyectos de Investigación 2009 - 2010 Servicio Salud Metropolitano Oriente	Burden of informal Caregivers of People with Alzheimer's Disease and other Dementias and study of cost of dementia	Cross-sectional clinical study. Caregiver burden and its determinant and cost of dementia	--	Finished	1- Slachevsky A., et al. Journal of Alzheimer's Disease 2013; 35: 297–306. 2- Hojman DA., et al. Plos One 2017; 12(3): e0172204.	--
Chile	Proyecto Fonis SAO 412065 2004	Red de demencias: capacitación a médicos de atención primaria e intervención psicoeducativa en cuidadores informale	Pilot study on capacitation and psychosocial intervention in dementia	30 caregivers and 30 GP	Finished	Slachevsky A., et al. Guía para Familiares y cuidadores 2017; LOM (Book)	--
Costa Rica	Award Number P01ES016731 from the National Institute of Environmental Health Sciences	Parkinson's and Alzheimer's diseases in Costa Rica: a feasibility study toward a national screening program.	Feasibility study	401elders	Finished	Wesseling, C., et al. Global health action 2013, 6, 23061.	--
Costa Rica	Award no. P01ES016731 from the National Institute of	Occupational pesticide exposure and screening tests for neurodegenerative disease	Screening pilot study	400 elders	Finished	Steenland K., et al. Environ Res. 2013 Jan; 120:96-101.	--

	Environmental Health Sciences	among an elderly population in Costa Rica.					
Costa Rica	NIH Fogarty International Center & National Institute on Aging grant: R21TW009258	Association of apolipoprotein E-e4 and dementia declines with age.	Association observational study	210 elders	Finished	Valerio, D., et al. Official journal of the American Association for Geriatric Psychiatry 2014; 22(10), 957–960.	--
Costa Rica	Memory Clinic of the National geriatrics and Gerontology Hospital, Dr Raul Blanco Cervantes, San Jose Costa Rica	Memory clinic experience under a social security health system in Costa Rica.	Observational study	3572 elders	Finished	Miranda-Valverde, E., et al. Dementia & neuropsychologia 2014, 8(4), 371–375.	--
Chile	Fondo de innovación para investigación en salud, Facultad de Medicina Universidad de Chile	Cultural adaptation of the Tailored Activity Program (TAP) for family caregivers of older adults with dementia in Chile	Implementacion Science Research	10 family caregivers and 10 persons with dementia, 3 implementers (occupational therapists), 6 stakeholders	Ongoing	Gajardo, J., et al. Innovation in Aging 2017, 1(S1), 1332.	--
Brazil	FAPESP - The State of São Paulo Research Foundation (grants #2006/55318-1 and #2009/09134-4)	Brain Bank of the Biobank for Aging Studies	Observational study	1200 brains	Ongoing	1- Grinberg LT., et al. Cell Tissue Bank 2007; 8:151-62. 2- Ehrenberg AJ., et al. J Alzheimers Dis. 2018. 3- Farfel JM., et al. Neurology 2013; 81:650-7. 4- Madeira C., et al. Transl Psychiatry. 2015; 5:e561. 5- Nascimento C., et al. Brain Pathol. 2016; 26:177-85. 6- Schlesinger D., et al. Mol Psychiatry 2011. 7- Suemoto CK., et al. Stroke. 2011; 42:3614-5. 8- Suemoto CK., et al. PLoS Med. 2017; 14:e1002267. 9- Theofilas P., et al. Alzheimers Dement. 2017; 13:236-246. 10- Villela D., et al. Front Genet. 2016; 7:107. 11- Villela D., et al. J Genet. 2014; 93:535-7.	--
Brazil	São Paulo Research Foundation (FAPESP) 2018/15571-7	Mapping the progression of Subjective Cognitive Decline to Mild Cognitive Impairment and Alzheimer's disease dementia with multimodal biomarkers	Prospective study	100 SCD, 100 MCI, 50 AD	Ongoing	--	--
Brazil	São Paulo Research Foundation (FAPESP) 2011/17092-0	Biomarkers in Alzheimer's disease and Mild Cognitive Impairment: evaluation of functional magnetic resonance imaging methods, plasmatic and cerebrospinal fluid markers	--	50 AD, 100 MCI, 100 controls	Finished	--	--

Chile	Comisión Nacional de Investigación Científica y Tecnológica - CONICYT, PFCHA/DOCTORADO BECA NACIONAL/2012 – 21120639.	Self-stigma in older adults with dementia: Addressing the matter in the Chilean context	Qualitative study	11 older adults with the diagnosis of early-stage dementia	Finished	Gajardo, J. The Journal of the Alzheimer's Association 2018.	--
Mexico	National Institutes of Health/National Institute on Aging (NIH R01AG051158)	The Cognitive Aging Ancillary Study (Mex-Cog)	Longitudinal Observational Study	2700 older adults	Ongoing	Gajardo, J. The Journal of the Alzheimer's Association 2018.	--
Mexico	National Institutes of Health/National Institute on Aging (grant number NIH R01AG018016) and the National Institute of Statistics and Geography	Mexican Health and Aging Study	Longitudinal Observational Study	15988 older adults	Ongoing	1- Aguilar-Navarro SG., et al. Salud Publica Mex. 2007; 49 Suppl 4:S467-74. 2- Al Hazzouri Adina Z., et al. Journal of Aging and Health 2011; 23(7):1027-1049. 3- Mejia-Arango S., et al. J Aging Health. 2011; 23(7):1050-74. 4- Mejía-Arango S. et al. Salud Publica Mex. 2007; 49 Suppl 4:S475-81. 5- Mejía S., et al. J Aging Health. 2006. 6- Melano-Carranza E., et al. Rev Panam Salud Publica. 2008; 23(5):295-302. 7- Montes de Oca VM., et al. Rev Kairos. 2008; 11(1):143-166. 8- Skirbekk V., et al. Proc Natl Acad Sci USA. 2012; 109(3):770-4. 9- Mejía-Arango S., et al. Rev Neurol. 2011; 53(7):397-405. 10- Mejía-Arango S., et al. Salud Publica Mex. 2015; 57 Suppl 1:S90-6. 11- Downer B., et al. Am J Alzheimers Dis Other Demen. 2016 Nov; 31(7):564-569. 12- Downer B., et al. J Alzheimers Dis. 2016 Mar 8; 52(1):191-203. 13- Veeranki SP., et al. J Aging Health. 2017 Apr; 29(3):454-473. 14- Downer B., et al. Ethn Health. 2018 Jan; 23(1):57-71. 15- Saenz J., et al. J Aging Health. 2017 Apr 1:898264317703560. 16- Saenz JL., et al. J Epidemiol Community Health. 2018 Jan; 72(1):21-26. 17- Díaz-Venegas C., et al. Aging & Mental Health 2012. 18- Saenz JL., et al. Aging Ment Health. 2018; Dec 27:1-10. 19- Aguilar-	--

						Navarro SG., et al. J Nutr Health Aging 2019; 23(3):227-231.	
Brazil	CNPq (National Research Council, Brazil - Grants 300424/2010-8 and 474712/2013-3 ) and FAPEMIG (Minas Gerais Research Foundation, Brazil - BPD-00082-12).	Investigation of diagnostic biomarkers in patients with mild cognitive impairment and Alzheimer disease.	Prospective study	300 individuals (MCI, AD, non-AD dementias, controls)	Ongoing	1- Corrêa JD., et al. Arq Neuropsiquiatr. 2011; 69: 455-9. 2- Magalhães CA., et al. Arq Neuropsiquiatr 2017; 75: 649-656. 3- Rocha NP., et al. J Alzheimers Dis 2018; 64: 1085-1090. 4- Magalhães CA., et al. J Clin Neurosci 2018; 56: 150-155. 5- Magalhães CA., et al. Clin Chem Lab Med 2019; 57: e77-e80.	--
Chile	Anillo Project ACP1403	From presbycusis to dementia: a basic and clinical approach	Cross-sectional	125 subjects. Control, MCI and AD; with or without hearing impairment	Ongoing	Belkhiria C., et al. Front. Aging Neurosci. 2019; 11:97.	--
Chile	INNOVA-CORFO Project	Advanced clinical trials and molecular composition of the internationally-positioned formula BrainUp-10	double blind randomized controlled trial	74 AD subjects	Ongoing	--	--
Uruguay, Chile, Spain, USA, Thailand, Bulgaria, Estonia, Slovenia, Bangladesh, South Africa, India	International Atomic Energy Agency	Enhancing Capacity of Neuroimaging and Biomarkers: Application in Early-stage Alzheimer's Disease with Comorbidities	Prospective study	300 individuals (MCI, AD)	Ongoing	--	--
Australia	NHMRC National Institute for Dementia Research	Non Alzheimer's disease degenerative dementias	Prospective study	300 individuals from dementia families (DLB, FTD, MND)	Ongoing	--	--
Australia	National Health and Medical Research Council of Australia	Frontotemporal dementia and motor neurodegenerative syndromes	Prospective study	> 600 individuals (FTD, MND)	Ongoing	1- Ahmed RM., et al. Nat Rev Neurol 2018; 14 (5):259-271. 2- Chen Y., et al. Ann Neurol 2018; 84(1):98-109.	--
Australia	National Health and Medical Research Council of Australia	Our MOB (Mind Our Brain): Dementia prevention across the life course with Aboriginal	Prospective study	~300 older adults	Ongoing	--	--

		Australians					
Uruguay, Argentina	Agencia Nariional de Investigación e Innovación (ANII), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)	Evaluación del Flujo Sanguíneo Cerebral, el Depósito de Amiloide y el Metabolismo Cerebral en pacientes con Afasia Primaria Progresiva	Pilot study	30 PPA patients	Finished	--	--
Colombia	Colciencias (111565741185)	Marcadores preclínicos para el diagnóstico diferencial de las demencias de inicio temprano	Prospective study	Older adults	Finished	--	--
Colombia	Colciencias (111565740786)	Estudio de iPCSs como modelo de la Enfermedad de Alzheimer familiar: Implicaciones terapéuticas	Trasversal study	Older adults	Finished	--	--
Colombia	Colciencias (111565741597)	Aspectos Clínicos y Genéticos en personas con quejas de memoria y deterioro cognitivo leve	Trasversal study	Older adults	Finished	--	--
Colombia	Colciencias (110171149904)	Caracterización Clínica y genética con grupos familiares con enfermedad de Alzheimer y trastornos de movimiento con patrones de herencia mendelianos	Prospective study	Older adults	Finished	--	--
Colombia	Colciencias(371-2011)	Los lóbulos frontales: estudio clínico y genético de la Demencia Frontotemporal.	Trasversal study	Older adults	Finished	--	--
Colombia-USA	NIH 1R21AG046499-01	YOUNG-ONSET DEMENTIA IN COLOMBIA	Prospective study	Older adults	Ongoing	--	--
Colombia-USA	GBHI ALZ UK-19-592004	Relationship between quantity, frequency and severity of alcohol, tobacco and drug consumption with the age of onset of EOAD in PSN1 E280A mutation carriers.	Prospective study	People with Early Onset Alzheimer's Disease	Ongoing	In preparation	--
Uruguay, Germany, Italy	EU-LAC HEALTH Joint Call for Proposal 2016/2017	Assessing mechanisms of Neurodegeneration and Neuroprotection by multimodal Neuroimaging: from healthy Aging to Alzheimer's Disease	Prospective study	240 individuals	Ongoing	--	--
Argentina (Buenos Aires)	Memory Laboratory of Zubizarreta Hospital career of clinical researcher, government of Buenos Aires, Argentina	Mild cognitive impairment: risk of dementia according to subtypes	Longitudinal Follow-up, cohort study of 127 patients diagnosed with MCI (Buenos Aires)	127> 60	--	--	--
Argentina (Buenos	Memory Laboratory of Zubizarreta Hospital,	Efficacy of a cognitive intervention program in patients	Follow-up Study of cognitive	Forty-six MCI participants	Finished	--	--



Aires)	Buenos Aires, Argentina	with mild cognitive impairment.	intervention program in MCI (1 year)				
Argentina (Buenos Aires)	career of clinical researcher, government of Buenos Aires, Argentina	Clinical and economic characteristics associated with direct costs of Alzheimer's, frontotemporal and vascular dementia in Argentina.	Cross-sectional study	104 patients with dementia (DAT = 44, FTD = 34, VaD = 26) were screened and matched by age and educational level with 29 healthy subjects	Finished	--	--
Argentina (Buenos Aires)	Memory Laboratory of Zubizarreta Hospital, Buenos Aires, Argentina	Cognitive, functional and behavioral factors associated with the burden of caring for geriatric patients with cognitive impairment or depression: evidence from a South American sample.	Cross-sectional study	258 caregiver-patient pairs	Finished	--	--
Argentina (Buenos Aires)	FLENI, Buenos Aires, Argentina	A biological classification for Alzheimer's disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the Argentine-Alzheimer's Disease Neuroimaging Initiative.	Cross-sectional study	--	Finished	Allegri RF., et al. Int Psychogeriatr. 2019 Mar 12:1-2.	--
Argentina (Buenos Aires)	arg.ADNI Buenos Aires, Argentina	Argentina-Alzheimer's disease neuroimaging initiative (Arg-ADNI): neuropsychological evolution profile after one-year follow up.	follow up study	51 participants	Finished	Méndez PC., et al. Arq Neuropsiquiatr. 2018 Apr; 76(4):231-240.	--
Argentina (Buenos Aires)	FLENI, Buenos Aires, Argentina	Biomarkers of Alzheimer's disease in mild cognitive impairment: Experience in a memory clinic from Latin America	Cross-sectional study	150 participants	Finished	Allegri RF., et al. Neurologia 2018; Apr 7.	--
Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	Risk of Conversion to Dementia in a Mild Behavioral Impairment Group Compared to a Psychiatric Group and to a Mild Cognitive Impairment Group	Follow up study	677 participants	Finished	Taragano FE., et al. J Alzheimers Dis. 2018; 62(1):227-238.	--
Argentina (Buenos Aires)	Arg. ADNI Buenos Aires, Argentina	Utility of the Spanish version of the Everyday Cognition scale in the diagnosis of mild cognitive impairment and mild dementia in an older cohort from the Argentina-ADNI.	Cross-sectional study	56 participants	Finished	Russo MJ., et al. Aging Clin Exp Res. 2018 Oct; 30(10):1167-1176.	--
Argentina (Buenos Aires)	arg.ADNI Buenos Aires, Argentina	Predicting episodic memory performance using different biomarkers: results from Argentina-Alzheimer's Disease	Cross-sectional study	56 participants	Finished	Russo MJ., et al. Neuropsychiatr Dis Treat. 2016 Sep 13; 12:2199-2206.	--

		Neuroimaging Initiative.					
argentina (Buenos Aires)	Memory Laboratory of Zubizarreta Hospital, Buenos Aires, Argentina	Validation of the Argentine version of the Memory Binding Test (MBT) for Early Detection of Mild Cognitive Impairment.	Cross-sectional study	88 subjects	Finished	Roman F. et al. Dement Neuropsychol. 2016 Jul-Sep; 10(3):217-226.	--
Argentina (Buenos Aires)	arg.ADNI Buenos Aires, Argentina	Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's Disease Neuroimaging Initiative).	Cross-sectional study	33 participants	Finished	Harris P., et al. Neuropsychiatr Dis Treat. 2015 Oct 7; 11:2599-604.	--
Argentina (Buenos Aires)		Cognitive impairment and risk factor prevalence in a population over 60 in Argentina.	Cross-sectional study	1453 individuals aged 60	Finished	Arizaga RL., et al. Dement Neuropsychol. 2014 Oct-Dec; 8(4):364-370.	--
Argentina (Buenos Aires)	FLENI, Buenos Aires, Argentina	Utility of the Spanish version of the FTLD-modified CDR in the diagnosis and staging in frontotemporal lobar degeneration.	Cross-sectional study	131 participants	Finished	Russo G., et al. J Neurol Sci. 2014; Sep 15; 344(1-2):63-8.	--
Argentina (Buenos Aires)	cemic Memory Clinic, Buenos Aires, Argentina	Insurance status and demographic and clinical factors associated with pharmacologic treatment of depression: associations in a cohort in Buenos Aires.	Cross-sectional study	100 patients	Finished	Machnicki G., et al. Value Health 2011; Jul-Aug; 14(5 Suppl 1):S13-5..	--
Argentina (Buenos Aires)	10/66 Dementia Group	A brief dementia screener suitable for use by non-specialists in resource poor settings--the cross-cultural derivation and validation of the brief Community Screening Instrument for Dementia.	Cross-sectional study	5 022 participants	Finished	Prince M., et al. Int J Geriatr Psychiatry 2011 Sep; 26(9):899-907.	--
Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	Clinical manifestations of geriatric depression in a memory clinic: toward a proposed subtyping of geriatric depression.	Cross-sectional study	139 participants	Finished	Dillon C., et al. J Affect Disord. 2011 Nov; 134(1-3):177-87.	--
Argentina (Buenos Aires)	10/66 Dementia Group	Subjective memory deficits in people with and without dementia: findings from the 10/66 dementia research group pilot studies in low- and middle-income countries.	Cross-sectional study	Two thousand six hundred ninety-two community-dwelling people aged 60	Finished	10/66 Dementia Research Group. J Am Geriatr Soc. 2009 Nov; 57(11):2118-24.	--
Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	Role of cognitive reserve in progression from mild cognitive impairment to dementia.	Follow-up Study	239 subjects	Finished	Allegri RF., et al. Dement Neuropsychol. 2010 Jan-Mar; 4(1):28-34.	--
Argentina (Buenos Aires)	Memory Laboratory of Zubizarreta Hospital, Buenos Aires, Argentina	Validity and reliability of the SF-36 administered to caregivers of patients with alzheimer's disease: evidence from a south american sample.	Cross-sectional study	Forty-eight caregivers of Alzheimer's disease patients	Finished	Machnicki G., et al. Dement Geriatr Cogn Disord. 2009; 28(3):206-12.	--

Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	Neuropsychiatric symptoms in mild cognitive impairment	Cross-sectional study	86 subjects	Finished	Demey I., et al. Vertex 2007; Jul-Aug; 18(74):252-7.	--
Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease.	Cross-sectional study	82 patients	Finished	Allegri RF., et al. Neuropsychiatr Dis Treat. 2006 Mar; 2(1):105-10.	--
Argentina (Buenos Aires)	CEMIC Memory Clinic, Buenos Aires, Argentina	A shortened form of the Spanish Boston naming test: a useful tool for the diagnosis of Alzheimer's disease]	Cross-sectional study	One hundred and three patients	Finished	Serrano C. et al. Rev Neurol. 2001 Oct 1-15; 33(7):624-7.	--
Argentina (Buenos Aires)	Memory Laboratory of Zubizarreta Hospital, Buenos Aires, Argentina	Butman J1, Allegri RF, Harris P, Drake M	Cross-sectional study	266	Finished	Butman J., et al. Medicina (B Aires). 2000; 60(5 Pt 1):561-4.	--
Argentina (Buenos Aires)	Memory Clinic, Milstein Hospital, Buenos Aires, Argentina	Argentine Validation of the Spanish Version of the Montreal Cognitive Assessment Test (MoCA-S) and its usefulness in Mild Cognitive Impairment and Dementia in adults over 60 years of age.	Cross-sectional study	399 subjects >60 years	Finished	Serrano CM., et al. 2019 (in preparation)	--
Argentina (Buenos Aires)	Memory Clinic, Milstein Hospital, Buenos Aires, Argentina	Epidemiological study on aging, depression and dementia in a center of C.A.B.A	Cross-sectional study	1877 subjets	Finished	Serrano CM., et al. 2019 (in preparation)	--
Argentina (Buenos Aires)	Memory Clinic, Italiano Hospital, Buenos Aires, Argentina	ALBA Screening Instrument (ASI): A brief screening tool for Lewy Body Dementia.	Cross-sectional study	427 subjects	Finished	Garcia Basalo MM., et al. Arch Gerontol Geriatr. 2017 May - Jun; 70:67-75.	--
Brazil (Minas Gerais)	CNPq (National Research Council, Brazil - Grant 436735/2018-0	Profile of biomarkers in cerebrospinal fluid and no peripheral blood of patients with Alzheimer's disease and mild cognitive impairment: recognition of mechanisms of Alzheimer's disease in the Brazilian population	Cross-sectional study	100 subjects	Ongoing	--	--
Brazil (Minas Gerais)	CNPq (National Research Council, Brazil - Grant 474208/2013-3; FAPEMIG (Minas Gerais Research Foundation, Brazil-grants APQ-02662-14)	Cohort of patients with Mild Cognitive Impairment - determination of risk factors for conversion to Alzheimer dementia	Cross-sectional study	350 subjects	Ongoing	1- Cintra, MTG et al. Journal of Geriatric Psychiatry 2018; v.33, p.e221 - e227. 2- De Paula JJ., et al. Frontiers in Psychology 2016; v.6, p.2061. 3-Vieira et al. International Journal of Geriatric Psychiatry 2016. , v.31, p.1337 - 1344.	--
Argentina (Buenos Aires)	Neurogenetics Unit. Hospital JM Ramos Mejia. (Grant PICT 2014-1999; Grants from Ministry of Health of Buenos Aires)	Research of the genetic basis of neurogenetic disorders in a tertiary hospital from Buenos Aires, Argentina	Observational study, genetics	~ 1000 subjects	Ongoing	1- Rodríguez-Quiroga SA., et al. Genet Res 2015; 97:e10. 2- Córdoba M., et al. PLoS One 2018; 13(2):e0191228.	--

Brazil	CNPq (National Research Council, Brazil - Grant No. 429079/2018-4)	Aging and AD biomarkers in middle-age and older adults with Down syndrome	Cross-sectional + longitudinal study	100 subjects (AD, DS and age-matched controls)	Ongoing	Bram JMF., et al. Current Psychiatry Reviews 2019; 15, 000-000 (in press)	--
Brazil	INCT (CNPq Grant No. 465412/2014-9; FAPESP Grant No.14/50873-3)	InBion: National Institute for Biomarkers in Neuropsychiatry.	Cross-sectional + longitudinal study	350 subjects (AD, MCI, MDD, BD, Schizophrenia and controls)	Ongoing	--	--
Brazil	FAPESP (Grant No. 2013/23135-9)	Early detection of cognitive impairments predictive of Alzheimer's disease using the eye movement analysis.	Cross-sectional	150 subjects (AD, MCI and controls)	Ongoing	Pereira ML., et al. Neuropsychiatr Dis Treat. 2014 9; 10:1273-85	--
Brazil	CNPq (Grant No. 466625/2014-6)	Expression and activity of amyloid precursor protein (APP)-secretases and glycogen synthase kinase-3 $\beta$ (GSK-3 $\beta$ ) activity in human platelets and neuronal cultures: effects of treatment with lithium and donepezil	--	Translational + clinical-laboratorial study (peripheral biomarkers)	Finished	Bram JMF., et al. J Alzheimers Dis. 2017; 55(4):1445-1451.	--
Brazil	Laboratory of Neuroscience (LIM-27), Institute of Psychiatry, University of Sao Paulo	Randomised controlled clinical trial to evaluate a Brazilian Outpatient version of the TAP method (Tailored Activity Program) in reducing neuropsychiatric symptoms between individuals with dementia	RCT (Non-pharmacological intervention); Registered in: Brazilian Clinical Trials Registry (ReBec), No. RBR-66DH44	34 participants (subjects with mild and moderate dementia with neuropsychiatric symptoms)	Finished	de Oliveira AM., et al. Int J Geriatr Psychiatry 2018.	--
Brazil	CNPq (National Research Council, Brazil - Grant No 557887/2009-7	Envelhecer mantendo funções: idosos do ano 2020.	Cross-sectional, observational	209 subjects	Finished	1- Murphy CFB., et al. J Am Acad Audiol. 2018 Jan; 29(1):5-14. 2- Silagi ML., et al. Cotas 2017; Nov 13; 29(6):e20160224. 3- Murphy CF., et al. Front Neurosci. 2016 Mar 10; 10:97. 4- Silagi ML., et al. Biomed Res Int. 2015; 2015:640657. 5- Silagi ML., et al. Dement Neuropsychol. 2013 Oct-Dec; 7(4):380-386. 6- Silagi ML., et al. Submitted to Journal of Neurological Sciences.	--
Brazil	CAPES (Coordination Center for Graduate School Enhancement - Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior)	Analysis of macrolinguistic aspects of narratives from individuals with Alzheimer's disease, mild cognitive impairment, and no cognitive impairment.		60 subjects	Finished	Toledo CM., et al. Alzheimers Dement (Amst) 2017; Sep 19;10:31-40.	--
Brazil	FAPESP - The State of São Paulo Research Foundation	Amyloid- $\beta$ depositionand neuropsychological profilein elderly with subjective cognitive	Cross-sectional + longitudinal study	77 subjects	Ongoing	--	--

	(2016/25000-1)	decline and SuperAgers					
Brazil	Alzheimer's Association (AARF-18-566005)	Characterization of tau astrogliopathy on aging and neurodegeneration	--	--	--	--	--

#### Annex 4: Initiatives for public policies and awareness

Countries	Source	Title	Initiative type	Status	Publications	Others
Americas	PAHO (Pan American Health Organization)	Strategy and Plan of action on Dementias in Older Persons	Regional initiative (2015)	Ongoing	<a href="https://www.alz.co.uk/sites/default/files/plans/PAHO-plan-of-action-on-dementias-in-older-persons.pdf">https://www.alz.co.uk/sites/default/files/plans/PAHO-plan-of-action-on-dementias-in-older-persons.pdf</a>	--
Argentina	Ministry of Health	Plan Nacional de Demencia de Argentina	Public Policy	Ongoing	--	--
Argentina, Chile, Uruguay	Inter-American Development Bank (IDB)	Behavioral insight group for social protection and health policies: A lifespan approach	Clinical-public policy: Manual and software platform for registry of dementia and regional data sharing	Ongoing	--	Potential extension to Brazil, Peru, Colombia
Brazil	Ministry of health. Decree No 2528/GM, dated October 19, 2006	National Policy on the Health of the Elderly (PNSPI)	National policy	Ongoing	Brasil. Ministério da Saúde (MS). Envelhecimento e saúde da pessoa idosa. Brasília: MS; 2006.	--
Chile	Ministry of Health - Government of Chile	Plan Nacional de Demencia de Chile (2017-2025)	Government dementia plan - National Policy	Ongoing	Report <a href="https://www.minsa.cl/wp-content/uploads/2017/11/PLAN-DE-DEMENCIA.pdf">https://www.minsa.cl/wp-content/uploads/2017/11/PLAN-DE-DEMENCIA.pdf</a>	1- Slachevsky A; Gajardo J (2019) Chile public health in Dementia Care: International Perspectives Editors Burns A, Robert Ph. Oxford University Press, Oxford. pp. 329-336. 2- Custodio N., et al. Front Aging Neurosci. 2017 Jul 13; 9:221.
Chile	Ministry of Health - Government of Chile	Línea Formativa Abordaje Integral de las Demencias.	Program of courses for training in dementia professional and non-professional health-care workers	Finished	--	--

Chile	Ministry of Health - Government of Chile	Guidelines for the Diagnosis of Dementia for Primary Care Physician	Ministry of Health initiative to harmonize dementia diagnosis by GP	Finished	--	Clínica Trastornos Cognitivos y Demencia en el Adulto Mayor, de los Drs. Patricio Fuentes, Archibaldo Donoso, Andrea Slachevsky, Alicia Villalobos, Luis Flores. MINSAL Chile
Chile	National Service for Older Adults (SENAMA), Ministry of Social Development	Design, implementation, and evaluation of an adult day care center for persons with dementia and family caregivers	Academic-governmental cooperation	Finished	Gajardo J., et al. Dementia 2017.	--
Chile	University of Chile	Dementia Policy Paper	Academic initiative to raise awareness on dementia plan and promote evidence-based public policy	Ongoing	Policy Paper. Prevención y abordaje integral de las demencias- Avances y desafíos para la política pública en materia de trastornos neurocognitivos	Release 20/06
Chile	Coprad (Corporation Professional de Alzheimer y otras demencias)	Propuesta de un Plan Nacional de Alzheimer y otras Demencias	Nonprofit civil association (Coprad) and profesional society (SONEPSYN) initiative to raise awareness on dementia and the needs of a dementia plan	Release	Report <a href="http://www.coprad.cl/wp-content/uploads/2018/01/pasos_coprad_alzheimer_chile.pdf">http://www.coprad.cl/wp-content/uploads/2018/01/pasos_coprad_alzheimer_chile.pdf</a>	Thumala D., et al. Health Syst Reform. 2017; Oct 2; 3(4):253-260
Chile	Chilean Society of Neurology, Psychiatry and Neurosurgery (Sonepsyn)	Guidelines for the diagnosis of dementia to specialist	Initiative for harmonize dementia practice at the specialist level	Finished	Guías clínicas de diagnóstico y tratamiento de las demencias. 2nd Edición Serie Azul. Santiago, Ediciones Sociedad de Neurología, Neurocirugía y Psiquiatría. Editor Behrens M	--
Colombia	Ministry of Health	Boletín de salud mental. Demencia	Government of Colombia	Ongoing	<a href="https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/">https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/</a>	--

					RIDE/ VS/ PP/ ENT/ Boletin-demencia -salud-mental.pdf	
Colombia	Ministry of Health	Guía de práctica clínica para el diagnóstico y el tratamiento del trastorno neurocognoscitivo mayor (Demencia)	Government of Colombia	Ongoing	<a href="http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_Demencia/GPC_Demencia_Completa.pdf">http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_Demencia/GPC_Demencia_Completa.pdf</a>	--
Costa Rica	CONAPAM (Consejo Nacional de la Persona Adulta Mayor) Presidencia de la república	Plan Nacional para la Enfermedad de Alzheimer y Demencias relacionadas esfuerzos compartidos (2014-2024)	Government dementia plan	Ongoing	<a href="http://www.conapam.go.cr/mantenimiento/Plan%20Nacional%20Alzheimer.pdf">http://www.conapam.go.cr/mantenimiento/Plan%20Nacional%20Alzheimer.pdf</a>	--
Cuba	International Journal of Cuban Health & Medicine 18 (4) Oct-Dec 2016	Cuba's Strategy for Alzheimer Disease and Dementia Syndromes	Dementia national health program (2016)	Ongoing	<a href="https://www.ncbi.nlm.nih.gov/pubmed/27829648">https://www.ncbi.nlm.nih.gov/pubmed/27829648</a>	--
Global	ADI (Alzheimer disease association)	World Alzheimer Report 2018. The state of the art of dementia research: New frontiers	Global report about all areas of dementia research world wide.	Published 2018	World Alzheimer Report 2018. Alzheimer's Disease International (ADI), London. September 2018 Copyright © Alzheimer's Disease International	--
Global	WHO (World health organization)	Global action plan on the public health response to dementia 2017 - 2025	A global plan including people with dementia and their families, to improve the health and wellbeing of those affected by dementia, both for present and future generations.	Published 2017	Global action plan on the public health response to dementia 2017 - 2025. World health organization 2017	--
Global, including Argentina, Brazil, Chile, Colombia, Costa Rica, El Salvador, Replublica Dominica, Mexico, Puerto Rico, and	Alzheimer's Association	International Society to Advance Alzheimer's Research and Treatment (ISTAART)	International professional society dedicated to dementia scientist, clinician and professionals. Provides opportunities to virtually link experts from around the world.	Ongoing	<a href="https://action.alz.org/personifyebusiness/default.aspx?tabid=1516">https://action.alz.org/personifyebusiness/default.aspx?tabid=1516</a>	--



Trinidad and Tobago						
Global, including Argentina, Brazil, Chile, Colombia, Costa Rica, El Salvador, Republica Dominica, Mexico, Puerto Rico, and Trinidad and Tobago	Alzheimer's Association	Worldwide Alzheimer's Disease Neuroimaging Initiatives (WW-ADNI)	Internatinational cosortium to bring together neuroimaging studies and other biomarkers from around the world with the objective to better understand and define the rate of progression of mild cognitive impairment and Alzheimer's disease.	Ongoing	<a href="https://www.alz.org/research/for_researchers/partnerships/wwadni/argentina_adni">https://www.alz.org/research/for_researchers/partnerships/wwadni/argentina_adni</a>	--
Global, including Argentina and Mexico	Alzheimer's Association	World Wide FINGERS	Worldwide consortium aimed at evaluating multimodal lifestyle interventions to prevent cognitive decline, building on the findings from the FINGERS study (Multicenter randomized controlled trial)	To be lauch soon	<a href="https://www.alz.org/wwfingers/overview.asp#projects">https://www.alz.org/wwfingers/overview.asp#projects</a>	--
Latinos in the U.S.	Massachusetts General Hospital (MGH).	Multicultural Alzheimer Prevention Program (MAPP).	Observational study.	Ongoing	<a href="https://mapp.mgh.harvard.edu/active-recruitment-l-habs/">https://mapp.mgh.harvard.edu/active-recruitment-l-habs/</a>	--
Mexico	BPO (Biblioteca de publicaciones oficiales del gobierno de Mexico)	Plan de acción Alzheimer y otras demencias, México 2014	Academic iniative aligned with the Mexican National Development Plan and Sectoral Health Program (2014)	Finished	<a href="https://bpo.sep.gob.mx/#/recurso/3456">https://bpo.sep.gob.mx/#/recurso/3456</a>	--
Mexico	Mexican academy of neurology	Guías prácticas del manejo de las demencias	Practical guide	Finished	Guías prácticas del manejo de las demencias. Rev Mex Neuroci. 2015; 16 (suplmento 1): S1-S129	--
Mexico and Brazil	Universities of Sussex and Cape Town, Alzheimer's Disease International and Dementia. Alliance International. The Federation of Brazilian Alzheimer's Associations (Febraz). The Federal University of São Paulo (UNIFESP). Instituto Nacional de Geriateía (INGER, Mexico).The	STRIDE(Strengthening responses to dementia in developing countries) project	A project that aims to build research capacity and provide much-needed evidence on dementia care in developing countries	Project	<a href="https://www.stride-dementia.org/project-partners">https://www.stride-dementia.org/project-partners</a>	--

	Mexican Federation of Alzheimer's (FEDMA)					
Mexico city (2015), Buenos Aires (2018), Sao Paulo (2019)	Alzheimer's Association	Alzheimer's Association International Conference (AAIC) Satellite Symposia	Latin american forums that provide an opportunity for researchers to identify common ground and seed/expand collaborations.	Ongoing	--	--
Peru	Ministry of Health (Law N° 30795)	Ley para la prevención y el tratamiento de Alzheimer y otras demencias	Government national action	Ongoing	<a href="https://busquedas.elperuano.pe/normaslegales/ley-para-la-prevencion-y-tratamiento-de-la-enfermedad-del-al-ley-n-30795-1660608-13/">https://busquedas.elperuano.pe/normaslegales/ley-para-la-prevencion-y-tratamiento-de-la-enfermedad-del-al-ley-n-30795-1660608-13/</a>	--
Uruguay	AUDAS (Asociación Uruguaya de Alzheimer y Similares)	Plan Nacional de Demencias para la República Oriental del Uruguay	Nonprofit civil association (AUDAS)	Ongoing	<a href="https://www.audas.org.uy/06_Informacion/AUDAS_Plan_Nacional_Demencias-Presentacion_Publica.pdf">https://www.audas.org.uy/06_Informacion/AUDAS_Plan_Nacional_Demencias-Presentacion_Publica.pdf</a>	--
Uruguay	Legislatura	Programa Nacional de Lucha Contra la Enfermedad de Alzheimer	Government Bill	2016	<a href="https://legislativo.parlamento.gub.uy/temporales/D2016090537-008527261.pdf">https://legislativo.parlamento.gub.uy/temporales/D2016090537-008527261.pdf</a>	--
Venezuela	Fundación Alzheimer Venezuela- Avaaz Venezuela	Alzheimer. Plan de acción nacional en políticas públicas.	Petition for a national dementia plan	Ongoing	<a href="https://www.alzheimervenezuela.org/article/firma-ahora-manana-podrias-ser-tu-unidos-por-el-al/">https://www.alzheimervenezuela.org/article/firma-ahora-manana-podrias-ser-tu-unidos-por-el-al/</a>	--